for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Ltd (ADR)

TEVA.N

Latest Trade

8.41USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

7.73

 - 

13.29

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
8.41
Open
--
Volume
--
3M AVG Volume
210.00
Today's High
--
Today's Low
--
52 Week High
13.29
52 Week Low
7.73
Shares Out (MIL)
1,103.01
Market Cap (MIL)
9,562.04
Forward P/E
3.35
Dividend (Yield %)
--

Next Event

Q4 2021 Teva Pharmaceutical Industries Ltd Earnings Release

Latest Developments

More

Teva Statement Following New York Jury Ruling In Opioids Trial

Quantum Genomics Signs Exclusive License Agreement With Teva Israel

Jiuzhou Pharmaceutical Agrees To Buy Pharma Chemical Firm For About $34 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teva Pharmaceutical Industries Ltd (ADR)

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Industry

Biotechnology & Drugs

Contact Info

5 Bazel St, P O B 3190

49131

Israel

+972.3.9267267

http://www.tevapharm.com

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Kaare Schultz

President, Chief Executive Officer, Director

Eliyahu Sharon Kalif

Chief Financial Officer, Executive Vice President

Galia Inbar

Executive Vice President - Global Communications, Brand and ESG, Chief Human Resource Officer

Richard Daniell

Executive Vice President - European Commercial

Key Stats

2.90 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

18.9K

2019

16.9K

2020

16.7K

2021(E)

16.2K
EPS (USD)

2018

2.920

2019

2.400

2020

2.570

2021(E)

2.520
Price To Earnings (TTM)
12.81
Price To Sales (TTM)
0.59
Price To Book (MRQ)
0.89
Price To Cash Flow (TTM)
4.42
Total Debt To Equity (MRQ)
226.87
LT Debt To Equity (MRQ)
200.98
Return on Investment (TTM)
2.11
Return on Equity (TTM)
1.55

Latest News

Latest News

Drugmaker Teva fueled opioid addiction in New York, jury finds

(This Dec. 30 story refiles to add dropped words "members of" in last paragraph)

Teva settles shareholder lawsuit over generic drug pricing for $420 million

Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.

Teva settles shareholder lawsuit over generic drug pricing for $420 mln

Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.

Teva fueled opioid addiction in New York, jury finds

Teva Pharmaceutical Industries Ltd fueled opioid addiction in New York state, a jury found on Thursday, a setback for a company still facing thousands of other opioid-related lawsuits around the United States.

Teva Israel enters medical cannabis market with new partnership

(This December 26 story was corrected after company clarified that the deal is with Teva Israel)

Teva, affiliates ignored safety to boost opioid sales, jury told

Lawyers for New York and one of its counties on Thursday urged jurors to find Teva Pharmaceutical Industries Inc liable for fueling opioid addiction in the state, saying the company and its affiliates pushed the drugs for off-label use and failed to monitor suspicious orders...

Novartis chairman says all options open for Sandoz unit - report

Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday.

Teva Pharm Q3 profit misses estimates, sees recovery into Q4

Israel-based Teva Pharmaceutical Industries reported third-quarter profit that missed estimates, citing lower North American sales but said a post-COVID recovery would allow it to meet its 2021 targets.

Teva Pharm unlikely to produce COVID vaccines, treatments, CEO says

Teva Pharmaceutical Industries said it was highly doubtful the company would co-produce COVID-19 vaccines or drugs to treat the illness, its chief executive officer said on Wednesday.

Teva halts output at U.S. drug plant after FDA flags concerns

Teva Pharmaceutical Industries has temporarily halted drug production at its Irvine plant in California to address issues raised by the U.S. Food and Drug Administration (FDA) after a recent inspection, the company said on Monday.

Teva must face government's kickback claims over Copaxone - judge

Israeli drugmaker Teva Pharmaceutical Industries Ltd must face a lawsuit by the U.S. government accusing it of using kickbacks paid through charitable foundations to boost sales of its multiple sclerosis drug Copaxone, resulting in false claims being submitted to Medicare.

Fed Circ. upholds some Teva migraine drug patents, invalidates others

The U.S. Court of Appeals for the Federal Circuit on Monday affirmed a Patent Trial and Appeal Board decision that upheld the validity of three Teva Pharmaceutical Industries Ltd's patents related to its migraine drug Ajovy, while also affirming PTAB decisions that invalidated...

Teva profit rise misses forecasts, sees lower 2021 sales

Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected rise in second-quarter profit on Wednesday but reaffirmed earnings guidance for the year despite saying that the COVID-19 pandemic could hurt sales.

Teva profit jumps 48% on strong demand for Huntington's disease treatment

Israel-based Teva Pharmaceutical Industries reported a 47.9% jump in second-quarter profit on Wednesday, helped by growth in Huntington's disease treatment Austedo and migraine product Ajovy.

IN BRIEF: Teva to pay $1.1 million in Intuniv antitrust settlement

Teva Pharmaceutical Industries Ltd has agreed to pay $1.1 million to settle antitrust claims by buyers of Shire's ADHD drug Intuniv, who accused Shire and Teva's predecessor Actavis of delaying the launch of a generic version of the drug through an illegal settlement.

New branded drugs helping Teva Pharm move closer to growth

Teva Pharmaceutical Industries is getting closer to returning to growth, its chief executive said, led by its two main branded drugs and following a corporate restructuring.

New branded drugs helping Teva Pharm move closer to growth

Teva Pharmaceutical Industries is getting closer to returning to growth, its chief executive said, led by its two main branded drugs and following a corporate restructuring.

Exclusive: Teva Pharm unlikely to reach deals to co-produce vaccines -CEO

Israel’s Teva Pharmaceutical Industries is not likely to reach deals with COVID vaccine makers to co-produce the vaccines although discussions are still ongoing, chief executive Kare Schultz told Reuters.

CORRECTED-UPDATE 3-California counties at trial argue J&J, other drugmakers fueled opioid epidemic

Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on Monday at the start of closely-watched trial.

Drug companies to face first opioid trial following pandemic delays

Four drugmakers, including Johnson & Johnson and Teva Pharmaceutical Industries Ltd, will go to trial on Monday over claims they helped fuel an opioid crisis that has resulted in nearly 500,000 overdose deaths in the United States.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up